Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Humanized bone facilitates prostate cancer metastasis and recapitulates therapeutic effects of zoledronic acid in vivo.

Landgraf M, Lahr CA, Sanchez-Herrero A, Meinert C, Shokoohmand A, Pollock PM, Hutmacher DW, Shafiee A, McGovern JA.

Bone Res. 2019 Oct 21;7:31. doi: 10.1038/s41413-019-0072-9. eCollection 2019.

2.

Microenvironment engineering of osteoblastic bone metastases reveals osteomimicry of patient-derived prostate cancer xenografts.

Shokoohmand A, Ren J, Baldwin J, Atack A, Shafiee A, Theodoropoulos C, Wille ML, Tran PA, Bray LJ, Smith D, Chetty N, Pollock PM, Hutmacher DW, Clements JA, Williams ED, Bock N.

Biomaterials. 2019 Nov;220:119402. doi: 10.1016/j.biomaterials.2019.119402. Epub 2019 Jul 31.

PMID:
31400612
3.

Bcl-2 inhibitors enhance FGFR inhibitor-induced mitochondrial-dependent cell death in FGFR2-mutant endometrial cancer.

Packer LM, Stehbens SJ, Bonazzi VF, Gunter JH, Ju RJ, Ward M, Gartside MG, Byron SA, Pollock PM.

Mol Oncol. 2019 Apr;13(4):738-756. doi: 10.1002/1878-0261.12422. Epub 2019 Jan 18.

4.

FGFR2-activating mutations disrupt cell polarity to potentiate migration and invasion in endometrial cancer cell models.

Stehbens SJ, Ju RJ, Adams MN, Perry SR, Haass NK, Bryant DM, Pollock PM.

J Cell Sci. 2018 Aug 10;131(15). pii: jcs213678. doi: 10.1242/jcs.213678.

5.

Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative.

Auguste A, Genestie C, De Bruyn M, Adam J, Le Formal A, Drusch F, Pautier P, Crosbie EJ, MacKay H, Kitchener HC, Powell M, Pollock PM, Mileshkin L, Edmondson RJ, Nout R, Nijman HW, Creutzberg CL, Bosse T, Leary A.

Mod Pathol. 2018 Dec;31(12):1851-1861. doi: 10.1038/s41379-018-0055-1. Epub 2018 Jun 28.

6.

hSSB1 phosphorylation is dynamically regulated by DNA-PK and PPP-family protein phosphatases.

Ashton NW, Paquet N, Shirran SL, Bolderson E, Kariawasam R, Touma C, Fallahbaghery A, Gamsjaeger R, Cubeddu L, Botting C, Pollock PM, O'Byrne KJ, Richard DJ.

DNA Repair (Amst). 2017 Jun;54:30-39. doi: 10.1016/j.dnarep.2017.03.006. Epub 2017 Apr 6.

7.

Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition.

Eggink FA, Van Gool IC, Leary A, Pollock PM, Crosbie EJ, Mileshkin L, Jordanova ES, Adam J, Freeman-Mills L, Church DN, Creutzberg CL, De Bruyn M, Nijman HW, Bosse T.

Oncoimmunology. 2016 Dec 9;6(2):e1264565. doi: 10.1080/2162402X.2016.1264565. eCollection 2017.

8.

FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.

Jeske YW, Ali S, Byron SA, Gao F, Mannel RS, Ghebre RG, DiSilvestro PA, Lele SB, Pearl ML, Schmidt AP, Lankes HA, Ramirez NC, Rasty G, Powell M, Goodfellow PJ, Pollock PM.

Gynecol Oncol. 2017 May;145(2):366-373. doi: 10.1016/j.ygyno.2017.02.031. Epub 2017 Mar 15.

9.

PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2mutant Endometrial Cancers.

Packer LM, Geng X, Bonazzi VF, Ju RJ, Mahon CE, Cummings MC, Stephenson SA, Pollock PM.

Mol Cancer Ther. 2017 Apr;16(4):637-648. doi: 10.1158/1535-7163.MCT-16-0415. Epub 2017 Jan 23.

10.

Endometrial cancer cells exhibit high expression of p110β and its selective inhibition induces variable responses on PI3K signaling, cell survival and proliferation.

Karlsson T, Krakstad C, Tangen IL, Hoivik EA, Pollock PM, Salvesen HB, Lewis AE.

Oncotarget. 2017 Jan 17;8(3):3881-3894. doi: 10.18632/oncotarget.13989.

11.

Loss of Rearranged L-Myc Fusion (RLF) results in defects in heart development in the mouse.

Bourke LM, Del Monte-Nieto G, Outhwaite JE, Bharti V, Pollock PM, Simmons DG, Adam A, Hur SS, Maghzal GJ, Whitelaw E, Stocker R, Suter CM, Harvey RP, Harten SK.

Differentiation. 2017 Mar - Apr;94:8-20. doi: 10.1016/j.diff.2016.11.004. Epub 2016 Dec 5.

PMID:
27930960
12.

The "melanoma-enriched" microRNA miR-4731-5p acts as a tumour suppressor.

Stark MS, Tom LN, Boyle GM, Bonazzi VF, Soyer HP, Herington AC, Pollock PM, Hayward NK.

Oncotarget. 2016 Aug 2;7(31):49677-49687. doi: 10.18632/oncotarget.10109.

13.

A Common Variant at the 14q32 Endometrial Cancer Risk Locus Activates AKT1 through YY1 Binding.

Painter JN, Kaufmann S, O'Mara TA, Hillman KM, Sivakumaran H, Darabi H, Cheng THT, Pearson J, Kazakoff S, Waddell N, Hoivik EA, Goode EL, Scott RJ, Tomlinson I, Dunning AM, Easton DF, French JD, Salvesen HB, Pollock PM, Thompson DJ, Spurdle AB, Edwards SL.

Am J Hum Genet. 2016 Jun 2;98(6):1159-1169. doi: 10.1016/j.ajhg.2016.04.012.

14.

The Prognostic and Predictive Value of Melanoma-related MicroRNAs Using Tissue and Serum: A MicroRNA Expression Analysis.

Stark MS, Klein K, Weide B, Haydu LE, Pflugfelder A, Tang YH, Palmer JM, Whiteman DC, Scolyer RA, Mann GJ, Thompson JF, Long GV, Barbour AP, Soyer HP, Garbe C, Herington A, Pollock PM, Hayward NK.

EBioMedicine. 2015 May 12;2(7):671-80. doi: 10.1016/j.ebiom.2015.05.011. eCollection 2015 Jul.

15.

miR-514a regulates the tumour suppressor NF1 and modulates BRAFi sensitivity in melanoma.

Stark MS, Bonazzi VF, Boyle GM, Palmer JM, Symmons J, Lanagan CM, Schmidt CW, Herington AC, Ballotti R, Pollock PM, Hayward NK.

Oncotarget. 2015 Jul 10;6(19):17753-63.

16.

Paralog-Specific Kinase Inhibition of FGFR4: Adding to the Arsenal of Anti-FGFR Agents.

Packer LM, Pollock PM.

Cancer Discov. 2015 Apr;5(4):355-7. doi: 10.1158/2159-8290.CD-15-0246.

17.

Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative.

Stelloo E, Bosse T, Nout RA, MacKay HJ, Church DN, Nijman HW, Leary A, Edmondson RJ, Powell ME, Crosbie EJ, Kitchener HC, Mileshkin L, Pollock PM, Smit VT, Creutzberg CL.

Mod Pathol. 2015 Jun;28(6):836-44. doi: 10.1038/modpathol.2015.43. Epub 2015 Feb 27.

18.

A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study.

Powell MA, Sill MW, Goodfellow PJ, Benbrook DM, Lankes HA, Leslie KK, Jeske Y, Mannel RS, Spillman MA, Lee PS, Hoffman JS, McMeekin DS, Pollock PM.

Gynecol Oncol. 2014 Oct;135(1):38-43. doi: 10.1016/j.ygyno.2014.07.083. Epub 2014 Jul 11.

19.

The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.

Byron SA, Chen H, Wortmann A, Loch D, Gartside MG, Dehkhoda F, Blais SP, Neubert TA, Mohammadi M, Pollock PM.

Neoplasia. 2013 Aug;15(8):975-88.

20.

Lineage-specific biomarkers predict response to FGFR inhibition.

Loch DC, Pollock PM.

Cancer Discov. 2012 Dec;2(12):1081-3. doi: 10.1158/2159-8290.CD-12-0486.

21.

Fibroblast growth factor receptor inhibition synergizes with Paclitaxel and Doxorubicin in endometrial cancer cells.

Byron SA, Loch DC, Pollock PM.

Int J Gynecol Cancer. 2012 Nov;22(9):1517-26. doi: 10.1097/IGC.0b013e31826f6806.

PMID:
23060048
22.

XIAP downregulation accompanies mebendazole growth inhibition in melanoma xenografts.

Doudican NA, Byron SA, Pollock PM, Orlow SJ.

Anticancer Drugs. 2013 Feb;24(2):181-8. doi: 10.1097/CAD.0b013e32835a43f1.

PMID:
23059386
23.

Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status.

Byron SA, Loch DC, Wellens CL, Wortmann A, Wu J, Wang J, Nomoto K, Pollock PM.

Mol Cancer. 2012 Oct 5;11:75. doi: 10.1186/1476-4598-11-75.

24.

FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features.

Byron SA, Gartside M, Powell MA, Wellens CL, Gao F, Mutch DG, Goodfellow PJ, Pollock PM.

PLoS One. 2012;7(2):e30801. doi: 10.1371/journal.pone.0030801. Epub 2012 Feb 23. Erratum in: PLoS One. 2012;7(2):doi/10.1371/annotation/0bfaecca-0f87-43fe-97cc-f2ae3ddeb6d5.

25.

Cellular settings mediating Src Substrate switching between focal adhesion kinase tyrosine 861 and CUB-domain-containing protein 1 (CDCP1) tyrosine 734.

Wortmann A, He Y, Christensen ME, Linn M, Lumley JW, Pollock PM, Waterhouse NJ, Hooper JD.

J Biol Chem. 2011 Dec 9;286(49):42303-15. doi: 10.1074/jbc.M111.227462. Epub 2011 Oct 12.

26.

Targeting mutant fibroblast growth factor receptors in cancer.

Greulich H, Pollock PM.

Trends Mol Med. 2011 May;17(5):283-92. doi: 10.1016/j.molmed.2011.01.012. Epub 2011 Mar 1. Review.

27.

p53 prevents progression of nevi to melanoma predominantly through cell cycle regulation.

Terzian T, Torchia EC, Dai D, Robinson SE, Murao K, Stiegmann RA, Gonzalez V, Boyle GM, Powell MB, Pollock PM, Lozano G, Robinson WA, Roop DR, Box NF.

Pigment Cell Melanoma Res. 2010 Dec;23(6):781-94. doi: 10.1111/j.1755-148X.2010.00773.x.

28.

Pictet-Spengler based synthesis of a bisarylmaleimide glycogen synthase kinase-3 inhibitor.

Magnus NA, Ley CP, Pollock PM, Wepsiec JP.

Org Lett. 2010 Aug 20;12(16):3700-3. doi: 10.1021/ol101405g.

PMID:
20704418
29.

FGFR2 mutations are rare across histologic subtypes of ovarian cancer.

Byron SA, Gartside MG, Wellens CL, Goodfellow PJ, Birrer MJ, Campbell IG, Pollock PM.

Gynecol Oncol. 2010 Apr;117(1):125-9. doi: 10.1016/j.ygyno.2009.12.002. Epub 2010 Jan 27.

PMID:
20106510
30.

Homodimerization controls the fibroblast growth factor 9 subfamily's receptor binding and heparan sulfate-dependent diffusion in the extracellular matrix.

Kalinina J, Byron SA, Makarenkova HP, Olsen SK, Eliseenkova AV, Larochelle WJ, Dhanabal M, Blais S, Ornitz DM, Day LA, Neubert TA, Pollock PM, Mohammadi M.

Mol Cell Biol. 2009 Sep;29(17):4663-78. doi: 10.1128/MCB.01780-08. Epub 2009 Jun 29.

31.

Active Notch1 confers a transformed phenotype to primary human melanocytes.

Pinnix CC, Lee JT, Liu ZJ, McDaid R, Balint K, Beverly LJ, Brafford PA, Xiao M, Himes B, Zabierowski SE, Yashiro-Ohtani Y, Nathanson KL, Bengston A, Pollock PM, Weeraratna AT, Nickoloff BJ, Pear WS, Capobianco AJ, Herlyn M.

Cancer Res. 2009 Jul 1;69(13):5312-20. doi: 10.1158/0008-5472.CAN-08-3767. Epub 2009 Jun 23.

32.

FGFR2 as a molecular target in endometrial cancer.

Byron SA, Pollock PM.

Future Oncol. 2009 Feb;5(1):27-32. doi: 10.2217/14796694.5.1.27. Review.

PMID:
19243295
33.

Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma.

Gartside MG, Chen H, Ibrahimi OA, Byron SA, Curtis AV, Wellens CL, Bengston A, Yudt LM, Eliseenkova AV, Ma J, Curtin JA, Hyder P, Harper UL, Riedesel E, Mann GJ, Trent JM, Bastian BC, Meltzer PS, Mohammadi M, Pollock PM.

Mol Cancer Res. 2009 Jan;7(1):41-54. doi: 10.1158/1541-7786.MCR-08-0021.

34.

A crystallographic snapshot of tyrosine trans-phosphorylation in action.

Chen H, Xu CF, Ma J, Eliseenkova AV, Li W, Pollock PM, Pitteloud N, Miller WT, Neubert TA, Mohammadi M.

Proc Natl Acad Sci U S A. 2008 Dec 16;105(50):19660-5. doi: 10.1073/pnas.0807752105. Epub 2008 Dec 5.

35.

Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation.

Byron SA, Gartside MG, Wellens CL, Mallon MA, Keenan JB, Powell MA, Goodfellow PJ, Pollock PM.

Cancer Res. 2008 Sep 1;68(17):6902-7. doi: 10.1158/0008-5472.CAN-08-0770. Erratum in: Cancer Res. 2008 Dec 1;68(23):10005.

36.

Common variation in the fibroblast growth factor receptor 2 gene is not associated with endometriosis risk.

Zhao ZZ, Pollock PM, Thomas S, Treloar SA, Nyholt DR, Montgomery GW.

Hum Reprod. 2008 Jul;23(7):1661-8. doi: 10.1093/humrep/den035. Epub 2008 Feb 18.

37.

Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes.

Pollock PM, Gartside MG, Dejeza LC, Powell MA, Mallon MA, Davies H, Mohammadi M, Futreal PA, Stratton MR, Trent JM, Goodfellow PJ.

Oncogene. 2007 Nov 1;26(50):7158-62. Epub 2007 May 21.

38.

Notch and NOXA-related pathways in melanoma cells.

Nickoloff BJ, Hendrix MJ, Pollock PM, Trent JM, Miele L, Qin JZ.

J Investig Dermatol Symp Proc. 2005 Nov;10(2):95-104. Review.

39.

Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells.

Qin JZ, Ziffra J, Stennett L, Bodner B, Bonish BK, Chaturvedi V, Bennett F, Pollock PM, Trent JM, Hendrix MJ, Rizzo P, Miele L, Nickoloff BJ.

Cancer Res. 2005 Jul 15;65(14):6282-93.

40.

p53-independent NOXA induction overcomes apoptotic resistance of malignant melanomas.

Qin JZ, Stennett L, Bacon P, Bodner B, Hendrix MJ, Seftor RE, Seftor EA, Margaryan NV, Pollock PM, Curtis A, Trent JM, Bennett F, Miele L, Nickoloff BJ.

Mol Cancer Ther. 2004 Aug;3(8):895-902.

41.

Deletion mapping suggests that the 1p22 melanoma susceptibility gene is a tumor suppressor localized to a 9-Mb interval.

Walker GJ, Indsto JO, Sood R, Faruque MU, Hu P, Pollock PM, Duray P, Holland EA, Brown K, Kefford RF, Trent JM, Mann GJ, Hayward NK.

Genes Chromosomes Cancer. 2004 Sep;41(1):56-64.

PMID:
15236317
42.

Microarray expression profiling in melanoma reveals a BRAF mutation signature.

Pavey S, Johansson P, Packer L, Taylor J, Stark M, Pollock PM, Walker GJ, Boyle GM, Harper U, Cozzi SJ, Hansen K, Yudt L, Schmidt C, Hersey P, Ellem KA, O'Rourke MG, Parsons PG, Meltzer P, Ringnér M, Hayward NK.

Oncogene. 2004 May 20;23(23):4060-7.

PMID:
15048078
43.

Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia.

Pollock PM, Cohen-Solal K, Sood R, Namkoong J, Martino JJ, Koganti A, Zhu H, Robbins C, Makalowska I, Shin SS, Marin Y, Roberts KG, Yudt LM, Chen A, Cheng J, Incao A, Pinkett HW, Graham CL, Dunn K, Crespo-Carbone SM, Mackason KR, Ryan KB, Sinsimer D, Goydos J, Reuhl KR, Eckhaus M, Meltzer PS, Pavan WJ, Trent JM, Chen S.

Nat Genet. 2003 May;34(1):108-12.

PMID:
12704387
44.

PTEN inactivation is rare in melanoma tumours but occurs frequently in melanoma cell lines.

Pollock PM, Walker GJ, Glendening JM, Que Noy T, Bloch NC, Fountain JW, Hayward NK.

Melanoma Res. 2002 Dec;12(6):565-75.

PMID:
12459646
45.

High frequency of BRAF mutations in nevi.

Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM, Moses TY, Hostetter G, Wagner U, Kakareka J, Salem G, Pohida T, Heenan P, Duray P, Kallioniemi O, Hayward NK, Trent JM, Meltzer PS.

Nat Genet. 2003 Jan;33(1):19-20. Epub 2002 Nov 25.

PMID:
12447372
46.

A genome-based strategy uncovers frequent BRAF mutations in melanoma.

Pollock PM, Meltzer PS.

Cancer Cell. 2002 Jul;2(1):5-7.

47.

Lucky draw in the gene raffle.

Pollock PM, Meltzer PS.

Nature. 2002 Jun 27;417(6892):906-7. No abstract available.

PMID:
12087387
48.

Mutations in exon 3 of the beta-catenin gene are rare in melanoma cell lines.

Pollock PM, Hayward N.

Melanoma Res. 2002 Apr;12(2):183-6.

PMID:
11930117
49.

Mutation analysis of the CDKN2A promoter in Australian melanoma families.

Pollock PM, Stark MS, Palmer JM, Walters MK, Aitken JF, Martin NG, Hayward NK.

Genes Chromosomes Cancer. 2001 Sep;32(1):89-94.

PMID:
11477665
50.

CDKN2A is not the principal target of deletions on the short arm of chromosome 9 in neuroendocrine (Merkel cell) carcinoma of the skin.

Cook AL, Pollock PM, Welch J, Walsh MD, Bowman RV, Baumann KC, Hayward NK, Leonard JH.

Int J Cancer. 2001 Aug 1;93(3):361-7.

Supplemental Content

Loading ...
Support Center